Instil Bio Inc
NASDAQ:TIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Instil Bio Inc
NASDAQ:TIL
|
US |
|
R
|
RLH Properties SAB de CV
BMV:RLHA
|
MX |
|
T
|
tripla Co Ltd
TSE:5136
|
JP |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
US |
|
Al Alamiya for Cooperative Insurance Company SJSC
SAU:8280
|
SA |
|
F
|
Finance of America Companies Inc
NYSE:FOA
|
US |
|
Hitachi Metals Ltd
TSE:5486
|
JP |
|
BRB Banco de Brasilia SA
BOVESPA:BSLI3
|
BR |
|
N
|
Nabati Foods Global Inc
CNSX:MEAL
|
CA |
|
Diversified Royalty Corp
TSX:DIV
|
CA |
|
Tharisa PLC
OTC:TIHRF
|
CY |
|
H
|
Hunan Er-Kang Pharmaceutical Co Ltd
SZSE:300267
|
CN |
|
Seadrill Ltd
OSE:SDRL
|
BM |
|
A
|
Adecco Group AG
LSE:0QNM
|
CH |
|
R
|
ReTo Eco-Solutions Inc
NASDAQ:RETO
|
CN |
|
A
|
Autodesk Inc
BMV:ADSK
|
US |
|
Arcadyan Technology Corp
TWSE:3596
|
TW |
|
Aqua Metals Inc
NASDAQ:AQMS
|
US |
|
Wuxi Lihu Corporation Limited
SZSE:300694
|
CN |
|
Gansu Yatai Industrial Development Co Ltd
SZSE:000691
|
CN |
|
G
|
G.M.I Technology Inc
TWSE:3312
|
TW |
|
MotorCycle Holdings Ltd
ASX:MTO
|
AU |
|
Lundin Mining Corp
TSX:LUN
|
CA |
Instil Bio Inc
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 412 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 412 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.
